The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Expected to Exhibit a CAGR of 4.34% during 2025-2035, Impelled by Advancements in Antiemetic Therapies

February 27, 2025 | Healthcare

VIEW FULL TABLE OF CONTENTS

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Outlook 2025-2035:

The 7 major Chemotherapy-Induced Nausea and Vomiting (CINV) markets are expected to exhibit a CAGR of 4.34% during 2025-2035. The market for Chemotherapy-Induced Nausea and Vomiting (CINV) is thriving due to the rapid acceptance of new antiemetic therapies that are user-friendly: long-acting oral formulations, transdermal patches, and subcutaneous injectables. All of these options offer relief to the patients while enhancing compliance with treatment regimens. Hence, advanced treatment options help in preventing really acute and delayed CINV therefore reducing hospitalization and IV infusion. With the introduction of neurokinin-1 (NK1) receptor antagonists and serotonin (5-HT3) receptor antagonists or cannabinoid-based therapies, nausea pathways in the body can be modulated to provide targeted relief, thus ensuring better symptomatic control with minimal side effects. The shift toward treatment combinations will boost overall efficacy and allow oncologists to tailor their antiemetic approaches to the patient's risk factors and chemotherapy type. Further, digital health solutions and a patient monitoring feedback mechanism will provide support for real-time tracking of symptoms for early intervention and improvement of patient outcomes and quality of life. Such technological advancements have thus made contemporary antiemetic therapy the preferred solution for both providers and patients so that interventions are less disruptive to cancer treatment rather than focusing on the patient's well-being.

Advances in Early Detection and Diagnostic Technologies: Driving the Chemotherapy-Induced Nausea and Vomiting (CINV) Market

Modern diagnostic and treatment technologies are significantly transforming the Chemotherapy-Induced Nausea and Vomiting (CINV) market, improving symptom management and patient outcomes. Pharmacogenomic testing is emerging as a vital tool in predicting individual responses to antiemetic therapies, allowing for personalized treatment strategies based on genetic profiles. Artificial intelligence (AI) and machine learning (ML) are being integrated into electronic health records (EHRs) to assess patient risk factors, optimize antiemetic regimens, and enhance predictive modeling for delayed or breakthrough CINV. AI-powered clinical decision support systems (CDSS) help oncologists refine treatment plans by analyzing patient histories and chemotherapy regimens, reducing the likelihood of treatment failure. Long-acting drug formulations, such as extended-release 5-HT3 receptor antagonists and transdermal NK1 receptor antagonists, offer sustained relief, minimizing the need for frequent dosing and improving adherence. Wearable biosensors and remote monitoring devices are enabling real-time tracking of nausea symptoms, hydration levels, and medication adherence, allowing for an early intervention and better disease management. Additionally, telemedicine and mobile health applications are expanding access to supportive care, enabling remote consultations, patient education, and symptom reporting, particularly for those undergoing outpatient chemotherapy. These advancements collectively contribute to enhanced CINV prevention, reduced hospital visits, and improved quality of life, driving growth in the global CINV market.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The Chemotherapy-Induced Nausea and Vomiting (CINV) market is expanding with the introduction of new therapies and advanced pharmacological treatments aimed at improving symptom management and patient outcomes. Next-generation antiemetics, including highly selective NK1 receptor antagonists, novel 5-HT3 receptor antagonists, and dopamine receptor modulators, are being developed to provide enhanced efficacy, longer duration of action, and reduced side effects, improving patient adherence and treatment success. Biological therapies, particularly monoclonal antibodies targeting neurokinin and serotonin pathways, are being explored for severe and refractory CINV cases, offering a new avenue for patients unresponsive to conventional antiemetics. Advancements in drug delivery systems, such as sustained-release injectables, transdermal patches, and orally disintegrating formulations, enhance drug bioavailability, ensuring consistent therapeutic effects while reducing dosing frequency. Additionally, cannabinoid-based therapies and novel gut-brain axis modulators are emerging as promising alternatives, helping manage nausea by targeting central and peripheral pathways. Combination therapies, integrating NK1 antagonists with corticosteroids or dopamine antagonists, are proving effective in addressing both acute and delayed phases of CINV, offering a comprehensive approach to symptom prevention. Precision medicine strategies, including pharmacogenomic testing, are enabling personalized antiemetic regimens based on genetic risk factors, optimizing patient responses. Meanwhile, digital health solutions, such as AI-powered symptom tracking apps and remote monitoring systems, are revolutionizing real-time management, improving patient engagement, and enabling proactive treatment adjustments. With continuous advancements in antiemetic drug development, precision medicine, and innovative delivery systems, the CINV market is poised for significant growth, enhancing both clinical outcomes and patient quality of life.

Marketed Therapies in Chemotherapy-Induced Nausea and Vomiting (CINV) Market

Varubi (Rolapitant): GlaxoSmithKline

Varubi (Rolapitant) is a selective neurokinin-1 (NK1) receptor antagonist used to prevent delayed-phase Chemotherapy-Induced Nausea and Vomiting (CINV). Unlike other NK1 antagonists, it has a long half-life (~180 hours), allowing for extended protection with a single dose in combination with 5-HT3 receptor antagonists and corticosteroids.

Akynzeo (Netupitant / Palonosetron): Helsinn

Akynzeo (Netupitant/Palonosetron) is a combination drug consisting of netupitant and palonosetron, designed in a fixed dose, and used for the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV). It consists of netupitant, which is an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in order to have increased and continuing antiemetic coverage against both the acute and delayed phases of CINV. This dual mechanism blocks both the nausea and vomiting pathways in order to enhance patient comfort and adherence to chemotherapy.

Sustol (Granisetron): Heron Therapeutics

Sustol (Granisetron) is a long-lasting 5-HT3 receptor antagonizer, which is indicated for prevention against Chemotherapy-Induced Nausea and Vomiting (CINV) due to moderately or greatly emetogenic chemotherapy regimens. Its extended-release formulation provides prolonged antiemetic protection for up to five days, reducing the need for multiple doses and improving patient adherence to CINV management.

Emend (aprepitant): Merck & Co

Emend (aprepitant) is a neurokinin-1 receptor antagonist that helps to prevent the short and long term effects of Chemotherapy-Induced Nausea and Vomiting (CINV). It blocks the neurotransmitter substance P which is involved directly in the emetic response, thus enhancing the activity of commonly used antiemetics including 5-HT3 receptor antagonists and corticosteroids. Emend is available in oral and intravenous formulations, improving patient compliance and symptom control.

Emerging Therapies in Chemotherapy-Induced Nausea and Vomiting (CINV) Market

APD421: Acacia Pharma

APD421 (Amisulpride IV) is a dopamine D2/D3 receptor antagonist developed for preventing and treating Chemotherapy-Induced Nausea and Vomiting (CINV). It has shown efficacy in managing breakthrough and delayed CINV, particularly in patients unresponsive to standard antiemetics. APD421 enhances antiemetic regimens when combined with 5-HT3 and NK1 receptor antagonists.

Drug Name	Company Name	MOA	ROA
APD421	Acacia Pharma	Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists	Intravenous

Detailed list of emerging therapies in Chemotherapy-Induced Nausea and Vomiting (CINV) is provided in the final report…

Leading Companies in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global Chemotherapy-Induced Nausea and Vomiting (CINV) market, several leading companies are at the forefront of developing integrated platforms to enhance the management of Chemotherapy-Induced Nausea and Vomiting (CINV). Some of the major players include Acacia Pharma, Novartis, Merck & Co, Heron Therapeutics, Helsinn, GlaxoSmithKline, and others. These companies are driving innovation in the Chemotherapy-Induced Nausea and Vomiting (CINV) market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for Chemotherapy-Induced Nausea and Vomiting (CINV).

Key Players in Chemotherapy-Induced Nausea and Vomiting (CINV) Market:

The key players in the Chemotherapy-Induced Nausea and Vomiting (CINV) market who are in different phases of developing different therapies are include Acacia Pharma, Novartis, Merck & Co, Heron Therapeutics, Helsinn, GlaxoSmithKline, and Others.

Key Players in Chemotherapy-Induced Nausea and Vomiting (CINV) Market

Regional Analysis:

The major markets for Chemotherapy-Induced Nausea and Vomiting (CINV) include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for Chemotherapy-Induced Nausea and Vomiting (CINV) while also representing the biggest market for its treatment. Recent advancements in Chemotherapy-Induced Nausea and Vomiting (CINV) treatment focus on novel antiemetic agents, neurokinin (NK1) and serotonin (5-HT3) receptor antagonists, and precision biologics to better manage symptoms and improve patient outcomes. New therapies, such as sustained-release antiemetic formulations, cannabinoid-based treatments, and gut-brain axis modulators, aim to enhance symptom control and minimize side effects. Cutting-edge gene-targeting treatments and monoclonal antibodies are also being explored to modulate neurotransmitter pathways, leading to more personalized and effective antiemetic options.

The diagnostic landscape for CINV is also evolving with pharmacogenomic testing, biomarker-driven treatment selection, and AI-powered predictive analytics, allowing for earlier risk assessment and tailored therapy regimens. Wearable biosensors and digital health platforms are enhancing real-time symptom monitoring and treatment adjustments, making care more proactive and accessible, particularly in underserved areas. Market growth is further fueled by regulatory approvals, increasing R&D investments, and collaborations between pharmaceutical companies, diagnostic firms, and research institutions. Telemedicine and AI-powered treatment optimization tools are expanding patient access to specialized care, while North America and Europe remain at the forefront of antiemetic innovation, driving global market expansion for CINV treatments.

Recent Developments in Chemotherapy-Induced Nausea and Vomiting (CINV) Market:

In January 2023, Glenmark Pharmaceuticals announced the launch of a new medication aimed at preventing Chemotherapy-Induced Nausea and Vomiting (CINV). This launch is part of an exclusive licensing agreement with Helsinn, a Swiss biopharmaceutical company specializing in cancer supportive care treatments. The partnership grants Glenmark the rights to market and distribute the drug, further expanding its oncology-related product portfolio.

Key information covered in the report

Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Chemotherapy-Induced Nausea and Vomiting (CINV) market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Chemotherapy-Induced Nausea and Vomiting (CINV) market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current Chemotherapy-Induced Nausea and Vomiting (CINV) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Expected to Exhibit a CAGR of 4.34% during 2025-2035, Impelled by Advancements in Antiemetic Therapies

Purchase Options Discount
Offer

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.